Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% ...
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...
Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham ...
Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...
In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...
The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...
The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...
The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...
Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...
In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback